Suchen
Harrow Inc
HROWZur Watchlist hinzufügen
41.500USD
-1.180-2.76%
Handelsschluss 06/25, 16:00（ET）Kurse um 15 Minuten verzögert
1.55BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Harrow Inc Unternehmen
Harrow, Inc. is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the North American market. The Company offers a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, BYQLOVI and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
Harrow Inc Informationen
BörsenkürzelHROW
Name des UnternehmensHarrow Inc
IPO-datumFeb 08, 2013
CEOMullery (Frank)
Anzahl der mitarbeiter382
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 08
Addresse1A Burton Hills Blvd
StadtNASHVILLE
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl37215
Telefon16157334731
Websitehttps://www.harrow.com/
BörsenkürzelHROW
IPO-datumFeb 08, 2013
CEOMullery (Frank)
Führungskräfte von Harrow Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Mark L. Baum, J.D.
Mr. Mark L. Baum, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
3.00M
+0.33%
Mr. Andrew R. Boll
Mr. Andrew R. Boll
President, Chief Financial Officer, Company Secretary
President, Chief Financial Officer, Company Secretary
814.68K
+0.43%
Dr. Adrienne L. Graves, Ph.D.
Dr. Adrienne L. Graves, Ph.D.
Independent Director
Independent Director
19.80K
+5.05%
Mrs. Lauren P. Silvernail
Mrs. Lauren P. Silvernail
Independent Director
Independent Director
19.80K
+5.05%
Mr. Perry J. Sternberg
Mr. Perry J. Sternberg
Lead Independent Director
Lead Independent Director
--
--
Mr. Amir Shojaei, Ph.D.
Mr. Amir Shojaei, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Randall E. Pollard, CPA
Mr. Randall E. Pollard, CPA
Chief Accounting Officer
Chief Accounting Officer
--
--
Mr. Frank Mullery
Mr. Frank Mullery
Chief Executive Officer of ImprimisRx
Chief Executive Officer of ImprimisRx
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Mark L. Baum, J.D.
Mr. Mark L. Baum, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
3.00M
+0.33%
Mr. Andrew R. Boll
Mr. Andrew R. Boll
President, Chief Financial Officer, Company Secretary
President, Chief Financial Officer, Company Secretary
814.68K
+0.43%
Dr. Adrienne L. Graves, Ph.D.
Dr. Adrienne L. Graves, Ph.D.
Independent Director
Independent Director
19.80K
+5.05%
Mrs. Lauren P. Silvernail
Mrs. Lauren P. Silvernail
Independent Director
Independent Director
19.80K
+5.05%
Mr. Perry J. Sternberg
Mr. Perry J. Sternberg
Lead Independent Director
Lead Independent Director
--
--
Mr. Amir Shojaei, Ph.D.
Mr. Amir Shojaei, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Harrow Inc?
Die fünf größten Anteilseigner von Harrow Inc sind: Mr. Mark L. Baum, J.D.
Wie viele Institutionen halten Anteile an Harrow Inc (HROW)?
Mit Stand vom 2026Q1 halten 418 Institutionen Anteile an Harrow Inc, mit einem Gesamtmarktwert von etwa 24.67M, was 66.17% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 347374.00 gestiegen.
